Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 9 | 18,754 | $40K |
| Grant or award | 7 | 141,925 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
88 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Tax withholding / forfeiture | Common Stock | 558 | $1.81 | $1K | ||
| Tax withholding / forfeiture | Common Stock | 284 | $1.81 | $514 | ||
| Mansoor Raza Mirza - Officer | Grant or award | Stock Option (Right to Buy) | 225,000 | $0.00 | - | |
| Peter Blume-Jensen - Officer | Tax withholding / forfeiture | Common Stock | 19,905 | $1.32 | $26K | |
| Erick Gamelin - Officer | Tax withholding / forfeiture | Common Stock | 403 | $1.39 | $560 | |
| Peter Blume-Jensen - Officer | Tax withholding / forfeiture | Common Stock | 59,766 | $1.39 | $83K | |
| Peter Blume-Jensen - Officer | Tax withholding / forfeiture | Common Stock | 490 | $1.39 | $681 | |
| Eric Devroe - Officer | Tax withholding / forfeiture | Common Stock | 613 | $1.39 | $852 | |
| Katharine Peterson - Officer | Tax withholding / forfeiture | Common Stock | 99 | $1.39 | $138 | |
| Tax withholding / forfeiture | Common Stock | 184 | $1.39 | $256 | ||
| Adam D. Levy - Officer | Tax withholding / forfeiture | Common Stock | 1,164 | $1.26 | $1K | |
| Tax withholding / forfeiture | Common Stock | 558 | $1.32 | $737 | ||
| Ivana Magovcevic-Liebisch | Grant or award | Stock Option (Right to Buy) | 20,275 | $0.00 | - | |
| PERCEPTIVE ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 437,881 | $1.41 | $617K | |
| PERCEPTIVE ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 298,886 | $1.34 | $401K | |
| PERCEPTIVE ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 1,054,669 | $1.95 | $2.06M | |
| PERCEPTIVE ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 215,283 | $1.56 | $336K | |
| PERCEPTIVE ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 250,000 | $1.41 | $353K | |
| Eric Devroe - Officer | Grant or award | Stock Option (Right to Buy) | 90,090 | $0.00 | - | |
| Peter Blume-Jensen - Officer | Grant or award | Stock Option (Right to Buy) | 225,226 | $0.00 | - | |
| Peter Blume-Jensen - Officer | Grant or award | Stock Option (Right to Buy) | 90,090 | $0.00 | - | |
| Grant or award | Stock Option (Right to Buy) | 67,567 | $0.00 | - | ||
| Erick Gamelin - Officer | Grant or award | Stock Option (Right to Buy) | 45,045 | $0.00 | - | |
| Rasmus Holm-Jorgensen - Officer | Grant or award | Stock Option (Right to Buy) | 90,090 | $0.00 | - | |
| Peter Blume-Jensen - Officer | Tax withholding / forfeiture | Common Stock | 19,910 | $6.44 | $128K | |
| Katharine Peterson - Officer | Tax withholding / forfeiture | Common Stock | 99 | $7.92 | $784 | |
| Erick Gamelin - Officer | Tax withholding / forfeiture | Common Stock | 402 | $7.92 | $3K | |
| Eric Devroe - Officer | Tax withholding / forfeiture | Common Stock | 613 | $7.92 | $5K | |
| Rasmus Holm-Jorgensen - Officer | Tax withholding / forfeiture | Common Stock | 368 | $7.92 | $3K | |
| Tax withholding / forfeiture | Common Stock | 184 | $7.92 | $1K | ||
| Peter Blume-Jensen - Officer | Tax withholding / forfeiture | Common Stock | 59,766 | $7.92 | $473K | |
| Peter Blume-Jensen - Officer | Tax withholding / forfeiture | Common Stock | 490 | $7.92 | $4K | |
| Tax withholding / forfeiture | Common Stock | 558 | $7.87 | $4K | ||
| Tax withholding / forfeiture | Common Stock | 284 | $6.98 | $2K |
This is as far as the anonymous view goes. Create a free account for all 88 ACRV filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Peter Blume-Jensen | Officer, Director | 14,036 | $31K | View on EDGAR |
Acrivon Therapeutics, Inc. (ACRV) had 15 insider filings in the last 90 days, with the most recent on 2026-08-27. The full record for ACRV runs to 88 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ACRV were filed in the last 90 days. 3 purchases are on record for this company.
9 insider sales of ACRV were filed in the last 90 days, totaling $40K.
This page tracks ACRV Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ACRV to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.